About Opsona Therapeutics - leaders in Innate Immune drug development
Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies, We are a leader in drug development in immunology research, with particular focus on the innate immunity pathways.
Since its founding in 2004, Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland.
Our research
Our aim is to deliver tomorrow's treatments from today's cutting edge research.
We are developing a unique and advanced range of drugs and vaccines to treat and prevent autoimmune and inflammatory diseases as well as technology for cancers and infectious diseases.
Our origins
Opsona is a spin-out from Trinity College Dublin, one of Ireland’s leading academic institutions with a core focus on immunology research.
Ireland is ranked one of the leading countries in the field of immunology research, and our founders have made a number of key discoveries in this exciting area. Recognised as key opinion leaders, our founders are:
- Professor Luke O'Neill
- Professor Kingston Mills
- Professor Dermot Kelleher
Partners and investors
Our approach is endorsed by commercial partnerships with leading international pharmaceutical companies, including Wyeth/Pfizer and CSL (Australia).
Opsona has a strong investor base, and our main investors are international and life-science focused:
- Novartis Venture Fund (Switzerland)
- Inventages Venture Capital (Switzerland)
- Seroba Kernel (Ireland)
- Fountain Healthcare Partners (Ireland)
- Roche Venture Fund (Switzerland)
- GenenFUND (USA)
- Enterprise Ireland (Ireland)